Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IntenSify: an Open-label Phase I Trial of the CYP3A Inhibitor Cobicistat and the Cytostatics Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma to Evaluate the Combination's Pharmacokinetics, Safety and Efficacy

NCT05494866 is registered in ClinicalTrials.gov with German Cancer Research Center as lead sponsor.

NCT NCT05494866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05494866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IntenSify: an Open-label Phase I Trial of the CYP3A Inhibitor Cobicistat and the Cytostatics Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma to Evaluate the Combination's Pharmacokinetics, Safety and Efficacy
Lead sponsor
German Cancer Research Center
Phase
Phase 1
Overall status
Terminated
Start date
December 7, 2022
Completion date
March 15, 2024
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced stage or metastatic pancreatic ductal adenocarcinoma, cyp3a inhibitor, pancreatic adenocarcinoma, pancreatic cancer, pancreatic neoplasm